Yang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Xu has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Wenbin Qian
Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
15 shared publications - Jiawei Zhang
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 shared publications - Xi Qiu
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 shared publications - Xuzhao Zhang
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13 shared publications - Boxiao Chen
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 shared publications - Dijia Xin
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Figure S1. A, control CAR (HBsAg CAR T), BCMA CAR and BCMA CAR-CD27 constructs were transduced into T cells, and CAR expression was detected by protein L assay. B, mock T, BCMA CAR and BCMA CAR-CD27 T cells were stained with anti-human CD27 antibodies. C, mock T and BCMA CAR-CD27 T cells were stained with fluorescence dye-labeled recombinant protein L and BCMA (rp), respectively. D, flow cytometry was used for detection of BCMA and CD70 on the cell surface of multiple cell lines. E, cell coculture was set-up as described in materials and methods. At Day 1 and 2 after coculture, supernatants were harvested for IFNγ measurement by ELISA. F, the transduced or non-transduced T cells were co-cultured with medium in the presence of anti-human CD107a for 1h, monensin was then added; and after 3h, cells were stained for CD3/CD4/CD8 antibodies and recombinant BCMA protein, and detected by flow cytometry. G and H, on day 15 after transduction, CAR-T cells were harvested and stained with CD4/CD8/ki67 antibodies and recombinant BCMA protein, and analyzed using flow cytometry (E); the percentage of Ki76+ cells in CD4+ and CD8+ CAR T cells were shown (F). * P<0.05.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Figure S1. A, control CAR (HBsAg CAR T), BCMA CAR and BCMA CAR-CD27 constructs were transduced into T cells, and CAR expression was detected by protein L assay. B, mock T, BCMA CAR and BCMA CAR-CD27 T cells were stained with anti-human CD27 antibodies. C, mock T and BCMA CAR-CD27 T cells were stained with fluorescence dye-labeled recombinant protein L and BCMA (rp), respectively. D, flow cytometry was used for detection of BCMA and CD70 on the cell surface of multiple cell lines. E, cell coculture was set-up as described in materials and methods. At Day 1 and 2 after coculture, supernatants were harvested for IFNγ measurement by ELISA. F, the transduced or non-transduced T cells were co-cultured with medium in the presence of anti-human CD107a for 1h, monensin was then added; and after 3h, cells were stained for CD3/CD4/CD8 antibodies and recombinant BCMA protein, and detected by flow cytometry. G and H, on day 15 after transduction, CAR-T cells were harvested and stained with CD4/CD8/ki67 antibodies and recombinant BCMA protein, and analyzed using flow cytometry (E); the percentage of Ki76+ cells in CD4+ and CD8+ CAR T cells were shown (F). * P<0.05.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Representativeness of Study Participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term responses has yet to be established. We investigated the feasibility of CBG-002, a CD27-armored BCMA CAR T-cell therapy, to improve clinical efficacy in patients with RRMM. We present preclinical data showing the activity of CBG-002 against myeloma and results from a phase I clinical trial (NCT04706936) evaluating its safety and efficacy in patients with RRMM. The primary endpoint was safety, as assessed by grade 3 or 4 adverse events (AE). Key secondary endpoints were overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 11 patients were enrolled and received CBG-002 therapy. Nine patients developed grade 1 or 2 cytokine release syndrome (CRS), whereas no patients experienced grade 3 or higher CRS or immune effector cell–associated neurotoxicity syndrome. Other grade 3 or higher AEs included neutropenia (72.7%), thrombocytopenia (45.5%), and anemia (36.4%). At a median follow-up of 16.7 months, the ORR was 81.8%, including a stringent complete response/complete response rate of 45.5%, very good partial response rate of 18.2%, and partial response rate of 18.2%, with a median DOR of 8.9 (range 1.8–21.9) months. The median OS was not reached, and the median PFS was 8.5 (2.7–22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T-cell therapy, demonstrated safety and clinical efficacy in patients with RRMM.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM); however, whether patients have long-term responses has yet to be established. We investigated the feasibility of CBG-002, a CD27-armored BCMA CAR T-cell therapy, to improve clinical efficacy in patients with RRMM. We present preclinical data showing the activity of CBG-002 against myeloma and results from a phase I clinical trial (NCT04706936) evaluating its safety and efficacy in patients with RRMM. The primary endpoint was safety, as assessed by grade 3 or 4 adverse events (AE). Key secondary endpoints were overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 11 patients were enrolled and received CBG-002 therapy. Nine patients developed grade 1 or 2 cytokine release syndrome (CRS), whereas no patients experienced grade 3 or higher CRS or immune effector cell–associated neurotoxicity syndrome. Other grade 3 or higher AEs included neutropenia (72.7%), thrombocytopenia (45.5%), and anemia (36.4%). At a median follow-up of 16.7 months, the ORR was 81.8%, including a stringent complete response/complete response rate of 45.5%, very good partial response rate of 18.2%, and partial response rate of 18.2%, with a median DOR of 8.9 (range 1.8–21.9) months. The median OS was not reached, and the median PFS was 8.5 (2.7–22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T-cell therapy, demonstrated safety and clinical efficacy in patients with RRMM.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-6
Teclistamab-Induced Localized Pleural Cavity Cytokine Release Syndrome in a Multiple Myeloma Patient Managed with Intrapleural Dexamethasone Administration
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific T-cell engager, has shown significant efficacy in patients with refractory multiple myeloma (MM). However, the clinical characteristics and optimal management strategies for localized cytokine release syndrome (CRS) remain poorly defined compared with systemic CRS. We report the case of a 57-year-old woman with refractory MM who developed both systemic and localized CRS following teclistamab therapy. She initially presented with grade 3 systemic CRS during step-up dosing phase, which partially resolved with intravenous methylprednisolone. However, interleukin-6 remained elevated in pleural effusions but not in serum, indicating localized pleural cavity CRS. Management with pleural fluid drainage combined with intrapleural dexamethasone successfully controlled the localized CRS. At two months, the patient achieved a partial response and continued teclistamab therapy. To our knowledge, this is among the first reported cases of teclistamab-associated localized pleural cavity CRS effectively managed with intrapleural dexamethasone.
- 1 April 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-6
Open AccessTeclistamab-Induced Localized Pleural Cavity Cytokine Release Syndrome in a Multiple Myeloma Patient Managed with Intrapleural Dexamethasone Administration
Teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific T-cell engager, has shown significant efficacy in patients with refractory multiple myeloma (MM). However, the clinical characteristics and optimal management strategies for localized cytokine release syndrome (CRS) remain poorly defined compared with systemic CRS. We report the case of a 57-year-old woman with refractory MM who developed both systemic and localized CRS following teclistamab therapy. She initially presented with grade 3 systemic CRS during step-up dosing phase, which partially resolved with intravenous methylprednisolone. However, interleukin-6 remained elevated in pleural effusions but not in serum, indicating localized pleural cavity CRS. Management with pleural fluid drainage combined with intrapleural dexamethasone successfully controlled the localized CRS. At two months, the patient achieved a partial response and continued teclistamab therapy. To our knowledge, this is among the first reported cases of teclistamab-associated localized pleural cavity CRS effectively managed with intrapleural dexamethasone.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
A, the peak CAR copies were compared between non-responders and responders (Mann-Whitney; P=0.006). B, CAR copies detected by qPCR following infusion of CBG-002 in patient 1. d: day; m: month.
- Open Access
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.
- 9 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
Median levels of serum CRP (A), IL-6 (B), IL-10 (C), TNFα (D) and IFNγ (E) during the CRS phase were measured in serial clinical samples stratified by dose cohorts.